Abstract:8568 Background: Low dosage computer tomography (LDCT) has been widely adopted as a sensitive method to detect early-stage lung cancer; however, debate regarding its accuracy and overdiagnosis is still ongoing. An accurate non-invasive test is needed to identify malignant nodules and reduce unnecessary invasive procedures. Studies show that plasma proteins and LDCT imaging features may be used to discriminate malignant pulmonary nodules from benign ones. We aimed to develop a combinatorial approach integrating serum protein markers and imaging features to improve the classification of pulmonary nodules. Methods: This study established a prospective research cohort, which enrolled 608 patients of pulmonary nodules. Plasma samples were collected to measure protein levels using Proximity Extension Assay (PEA) technology. The imaging features of the pulmonary nodules were extracted using the python 'radiomics' package. Following feature extraction, a deep learning networks model was built using training cases. The model was then tested in the testing set to evaluate its accuracy and robustness. Results: From the study cohort, 184 benign (BN) and 184 malignant (MT) samples matched for sex and age were chosen to have a representative training set. The rest 240 samples (81 BN and 159 MT) were used as a testing set. Image features were extracted from 448 patients (119 BN and 153 MT in training; 57 BN and 119 MT in testing) with raw LDCT image available. In the testing set, the model trained using only protein levels had an AUC of 0.83 [0.782-0.877] (sensitivity = 71.1% [95% CI 63.6-77.6]; specificity = 82.7% [73.1-89.4]) when classifying plasma samples of lung cancers from those of benign nodules. In comparison, the imaging features-only model had an AUC of 0.874 [0.821-0.916] (sensitivity = 81.5 [73.6-87.5]; specificity = 73.7 [61.0-83.4]). The combinatorial model integrating both protein and imaging features had an AUC of 0.878 [0.830-0.921] (sensitivity = 83.2% [75.5-88.8]; specificity = 77.2% [64.8-86.2]). Notably, the combinatorial model was highly sensitive for early-stage lung cancer, achieving a sensitivity of 93.1% [78.0-98.1] when classifying stage-0 lung cancer cases(n = 29) and 94.8% [85.9-98.2] for stage-I cases (N = 58). Its sensitivity for stage II-IV (n = 7) and clinically diagnosed lung cancers cases (n = 25) were 100% [64.6-100] and 40.0% [23.4-59.3], respectively. Conclusions: This study aimed to construct a model to distinguish malignant pulmonary nodules from benign lung diseases using protein levels and LDCT imaging features. The resulted combinatorial model showed by utilizing both types of features, it was able to accurately differentiate benign and malignant pulmonary nodules, suggesting it may provide guidance for the clinical management of these nodules.

Overcoming Obstacles In Pathological Diagnosis Of Pulmonary Nodules Through Circulating Tumor Cell Enrichment

Isolation and characterization of living circulating tumor cells in patients by immunomagnetic negative enrichment coupled with flow cytometry.

Preliminary Investigation of the Clinical Significance of Detecting Circulating Tumor Cells Enriched from Lung Cancer Patients

CTCs Detection and Whole-exome Sequencing Might Be Used to Differentiate Benign and Malignant Pulmonary Nodules.

[The Value of Circulating Tumor Cells Detected by Chromosome Centromere Probe Identification in Diagnosis of Non-Small Cell Lung Cancer].

A Noninvasive Multianalytical Approach for Lung Cancer Diagnosis of Patients with Pulmonary Nodules

Value of circulating tumor cell assisting low-dose computed tomography in screening pulmonary nodules based on existing liquid biopsy techniques: a systematic review with meta-analysis and trial sequential analysis

A combinatorial model of plasma proteins and LDCT imaging and the diagnosis of pulmonary nodules.

Enhancing the differential diagnosis of small pulmonary nodules: a comprehensive model integrating plasma methylation, protein biomarkers, and LDCT imaging features

Value of circulating tumor cells in the diagnosis and treatment of solitary pulmonary nodules

Precision patient selection for improved detection of circulating genetically abnormal cells in pulmonary nodules

Effect of Circulating Tumor Cells Combined with Negative Enrichment and CD45-FISH Identification in Diagnosis, Therapy Monitoring and Prognosis of Primary Lung Cancer

Non-invasive diagnosis of pulmonary nodules by circulating tumor DNA methylation: A prospective multicenter study

The Pulmonary Nodule "discovered" by Pneumonia: a Case Report.

Cmar_a_245425 2069..2078

Clinical test on circulating tumor cells in peripheral blood of lung cancer patients, based on novel immunomagnetic beads

The capture of circulating tumor cells by Labyrinth system as a tool for early stage lung cancer detection

Detection of PD-L1 Expression and Its Clinical Significance in Circulating Tumor Cells from Patients with Non-Small-Cell Lung Cancer

Combined Peripheral Natural Killer Cell and Circulating Tumor Cell Enumeration Enhance Prognostic Efficiency in Patients with Metastatic Triple-Negative Breast Cancer.

Clinical Utility of Circulating Genetically Abnormal Cells Within Low-Dose Computed Tomography Lung Cancer Screening: A Correlative MCPND Trial Study.

Cell-free DNA assay for malignancy classification of high-risk lung nodules.